The short answer
Bliddal and colleagues published once-weekly semaglutide in persons with obesity and knee osteoarthritis in the New England Journal of Medicine in October 2024. The trial, NCT05064735, enrolled 407 participants with co-primary endpoints of percentage change in body weight and change in WOMAC pain score.
Key facts
- Registration
- NCT05064735
- Registered acronym
- None
- Phase
- 3
- Enrolment
- 407
- Status
- Completed
- Primary completion
- 24 July 2023
- Co-primary 1
- Percentage change in body weight
- Co-primary 2
- Change in WOMAC pain score
- Published
- NEJM, 31 October 2024 (PMID 39476339)
Why two co-primary endpoints is the notable design choice
The registry lists both percentage change in body weight and change in WOMAC pain score as primary outcomes. Requiring a trial to move two endpoints is a harder test than either alone, and it reflects the specific claim being made. The claim is not that the drug reduces weight, which was established, but that doing so changes what the joint disease does to people.
What WOMAC measures
The Western Ontario and McMaster Universities Osteoarthritis Index is a patient-reported instrument covering pain, stiffness and physical function. It asks people what they experience rather than measuring cartilage on a scan, which makes it a symptomatic endpoint. Symptoms are what bring people with osteoarthritis to clinicians.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the mechanical argument is strong here
The knee bears load, and the force it experiences during walking is several times body weight because muscle contraction across the joint adds to gravitational load. Reducing body mass therefore reduces joint force by a multiple of the mass lost. Unlike most indications for this class, the primary mechanism requires nothing beyond the weight change itself.
What it does not establish
Structural change. A symptomatic improvement is not evidence that cartilage was preserved or that disease progression slowed. Those are separate endpoints requiring imaging and much longer follow-up, and osteoarthritis has a long history of symptomatic effects that did not translate into structural ones.
The naming point, for the third time
NCT05064735 carries no registered acronym. This site has now found three widely discussed trials in the same position, the CagriSema head-to-head and the tirzepatide adolescent Phase 3 being the others. Searching a programme name on ClinicalTrials.gov can return nothing while the trial exists under its number.
How this fits the indication pattern
Cardiovascular events, kidney events, liver histology, heart failure, walking capacity in peripheral artery disease and now joint symptoms. The pattern is a metabolic agent being assessed organ system by organ system, with osteoarthritis unusual in that the proposed mechanism is mechanical rather than metabolic.
The boundary
Semaglutide is a licensed medicine and this was a registered trial conducted under clinical supervision. Nothing supplied on this site is semaglutide, is related to it, or is an alternative to any treatment for osteoarthritis.
Frequently asked questions
What were the trial's primary endpoints?
Two: percentage change in body weight and change in WOMAC pain score. Moving both is a harder test than either alone.
What is WOMAC?
A patient-reported instrument covering pain, stiffness and physical function in osteoarthritis. It measures symptoms rather than joint structure.
Does it show the joint disease was slowed?
No. Symptomatic improvement is not structural evidence, which would require imaging endpoints and much longer follow-up.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBliddal H et al., Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. NEJM 2024 (PMID 39476339)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Semaglutide in obesity and knee osteoarthritis (NCT05064735)clinicaltrials.gov
- PubMedGatto A et al., The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Curr Rev Musculoskelet Med 2025 (PMID 40372699)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management - which is the finding.
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70-90% discounts.
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.
- Comparing an Operation With an InjectionA 2026 network meta-analysis compared metabolic and bariatric surgery against GLP-1 receptor agonists. Why the comparison is harder than it looks.
- Does Amylin Need a GLP-1 Partner?CagriSema pairs amylin with semaglutide and missed non-inferiority. A 2026 review surveys long-acting amylin peptides being developed on their own.